Self-medication with anxiolytics and antidepressants: main risk factors and repercussions

Keywords: Self-medication, antidepressants, anxiolytics, consequences, risk factors

Abstract

Self-medication refers to the consumption of medications on one's own initiative and without a prescription from a health professional to treat self-diagnosed problems or by an individual who is not medically qualified. Self-medication is a common practice in the world and is generally practiced in both developed and developing countries, with a prevalence ranging between 12.1% and 92.8%, respectively. The aim of this article is to provide information on self-medication with antidepressants and anxiolytics, the consequences that the different groups of drugs bring with them when not properly implemented, the factors that influence the decision making to carry out this practice, so that the general population and especially health professionals, both those who are in training and those who have already graduated, be aware of the risks with this type of medication, identify and act in a timely manner in the event of intoxication, providing patient education on the proper use of them, and positively influence the population to have a positive impact on the statistics., avoiding morbimortality, without leaving out the promotion of mental health, by recognizing the risk factors and taking actions for a timely intervention on the risk groups.

Downloads

Download data is not yet available.

References

Behzadifar M, Behzadifar M, Aryankhesal A, Ravaghi H, Baradaran HR, Sajadi HS, et al. Prevalence of self-medication in university students: systematic review and meta-analysis. East. Mediterr. Health. J. 2020;26(7):846–857.

Makowska M, Boguszewki R, Nowakowski M, Podkowińska M. Self-medication-related behaviors and Poland’s COVID-19 lockdown. Int. J. Environ Res. Public Health. 2020;17(22):8344.

Fetensa G, Tolossa T, Etafa W, Fekadu G. Prevalence and predictors of self-medication among university students in Ethiopia: a systematic review and meta-analysis. J. Pharm Policy Pract. 2021;14(1):107.

Reyes-Guillén I, Vázquez Gutiérrez R, Ávila Solís FJ. Red de Investigación en Salud Pública y Atención a problemas del Desarrollo, Caracterización de la práctica de automedicación en jóvenes universitarios. Espacio I+D. 2017;6(15):43–53.

Zeru N, Fetene D, Geberu DM, Melesse AW, Atnafu A. Self-medication practice and associated factors among university of Gondar college of medicine and health sciences students: A cross-sectional study. Patient Prefer Adherence. 2020;14: 1779–1790.

Hashemzaei M, Afshari M, Koohkan Z, Bazi A, Rezaee R, Tabrizian K. Knowledge, attitude, and practice of pharmacy and medical students regarding self-medication, a study in Zabol University of Medical Sciences; Sistan and Baluchestan province in south-east of Iran. BMC Med. Educ. 2021;21(1):49.

Brauer R, Alfageh B, Blais JE, Chan EW, Chui CSL, Hayes JF, et al. Psychotropic medicine consumption in 65 countries and regions, 2008-19: a longitudinal study. Lancet Psychiatry. 2021;8(12):1071–1082.

Sekhon S, Gupta V. Mood Disorder. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022. Available from: https://www.ncbi.nlm.nih.gov/books/NBK558911/

Bennett D, Davidson G, Niv Y. A model of mood as integrated advantage. Psychol. Rev. 2022;129(3):513–541.

Hirdes JP, Morris JN, Perlman CM, Saari M, Betini GS, Franco-Martin MA, et al. Mood disturbances across the continuum of care based on self-report and clinician rated measures in the inter RAI suite of assessment instruments. Front Psychiatry. 2022;13:787463.

Baena A, Maurilia Z, Sandoval Villegas A, Urbina CC, Norma T, Juárez H, et al. LOS TRASTORNOS DEL ESTADO DE ÁNIMO [Internet]. Unam.mx. Available from: http://revista.unam.mx/vol.6/num11/art110/nov_art110.pdf

Maurer DM, Raymond TJ, Davis BN. Depression: Screening and Diagnosis. Am. Fam. Physician. 2018;98(8):508-515

Chen X, Li M, Gong H, Zhang Z, Wang W. Factors influencing adolescent anxiety: The roles of mothers, teachers and peers. Int. J. Environ. Res. Public Health. 2021;18(24):13234.

Lopez M, Mejia C, Vargas M. Ansiedad y depresión como factores de riesgo en el inicio temprano del consumo de tabaco, alcohol y otras drogas [Internet]. www.cij.gob.mx; 2018. Available from: http://www.biblioteca.cij.gob.mx/publicaciones/prevencion/libro2.pdf

Hur J, Stockbridge MD, Fox AS, Shackman AJ. Dispositional negativity, cognition, and anxiety disorders: An integrative translational neuroscience framework. Srinivasan N, editor. Prog. Brain Res. 2019;247: 375–436.

American Psychiatric Association-APA. Manual Diagnóstico Y Estadístico De Los Trastornos Mentales DSM-5 [Internet]. Madrid: Editorial Médica Panamericana; 2014. Available from: https://www.federaciocatalanatdah.org/wp-content/uploads/2018/12/dsm5-manualdiagnsticoyestadisticodelostrastornosmentales 161006005112.pdf.

Penninx BW, Pine DS, Holmes EA, Reif A. Anxiety disorders. Lancet. 2021; 397 (10277): 914-927.

Kandola A, Stubbs B. Exercise and anxiety. Adv. Exp. Med. Biol. 2020;1228: 345–352.

Garakani A, Murrough JW, Freire RC, Thom RP, Larkin K, Buono FD, Iosifescu DV. Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options. Front Psychiatry. 2020;11: 595584

Gaitán-Rossi P, Pérez-Hernández V, Vilar-Compte M, Graciela T-B. Prevalencia mensual de trastorno de ansiedad generalizada durante la pandemia por Covid-19 en México. Salud Publica Mex. 2021;63(4): 478–485.

Delpino FM, da Silva CN, Jerônimo JS, Mulling ES, da Cunha LL, Weymar MK, et al. Prevalence of anxiety during the COVID-19 pandemic: A systematic review and meta-analysis of over 2 million people. J. Affect Disord. 2022;318: 272–282.

Anjum A, Hossain S, Hasan MT, Uddin ME, Sikder MT. Anxiety among urban, semi-urban and rural school adolescents in Dhaka, Bangladesh: Investigating prevalence and associated factors. PLoS One. 2022;17(1): e0262716.

Hammen C. Risk factors for depression: An autobiographical review. Annu. Rev. Clin. Psychol. 2018;14(1):1–28.

Arrarás JI, Manrique E. How depression and its treatment are perceived. An Sist. Sanit Navar. 2019;42(1):5–8.

Airaksinen J, Komulainen K, García-Velázquez R, Määttänen I, Gluschkoff K, Savelieva K, et al. Subclinical hypothyroidism and symptoms of depression: Evidence from the National Health and Nutrition Examination Surveys (NHANES). Compr. Psychiatry. 2021;109(152253):152253.

WHO. Depresión [Internet]. Who.int. 2021. Available from: https://www.who.int/es/news-room/fact-sheets/detail/depression

Cladder-Micus MB, Speckens AEM, Vrijsen JN, T Donders AR, Becker ES, Spijker J. Mindfulness-based cognitive therapy for patients with chronic, treatment-resistant depression: A pragmatic randomized controlled trial. Depress Anxiety. 2018;35(10):914–924.

Oliffe JL, Rossnagel E, Seidler ZE, Kealy D, Ogrodniczuk JS, Rice SM. Men’s depression and suicide. Curr. Psychiatry Rep. 2019;21(10):103

McKetta S, Keyes KM. Oral contraceptive use and depression among adolescents. Ann Epidemiol. 2019;29:46–51.

Mejia R. Cuadro Básico y Catálogo Institucional Edición 2018 Psiquiatría [Internet]. 2018. Available from: https://www.salud.cdmx.gob.mx/storage/app/media/2018-2024/medicamentos/FICHAS%20TECNICAS/Psiq%20Ed.%202018.pdf

León EC-, Uribe MPO, Gómez CS. Los antidepresivos inhibidores selectivos de recaptura de serotonina (ISRS, ISR-5HT) [Internet]. Org.mx. 2008. Available from: https://www.scielo.org.mx/pdf/sm/v31n4/v31n4a8.pdf

Pérez Esparza R. Tratamiento farmacológico de la depresión: actualidades y futuras direcciones. Rev. Fac. Med. Univ. Nac. Auton. Mex. 2017;60(5):7–16.

IMSS. Grupos Terapéuticos del Cuadro Básico de Medicamentos [Internet]. 2019. Available from: https://www.imss.gob.mx/sites/all/statics/pdf/cuadrosbasicos/CBM.pdf

Vasquez Arancibia V, Lara B, Basauri S. Intoxicación por antidepresivos tricíclicos. ARS med. 2023;48(1):31-38.

Huffman JC, Beach SR, Stern TA. Efectos secundarios de los psicotrópicos [Internet]. Sncpharma.com. Available from: https://sncpharma.com/wp-content/uploads/2020/12/51.-Efectos secundarios-de-los-psicotr%C3%B3picos.pdf

Viviana D, Trobo D, Tortorella MN, Speranza N, Amigo C, Laborde A, et al. Perfil epidemiológico de las intoxicaciones por benzodiazepinas recibidas en el Centro de Información y Asesoramiento Toxicológico uruguayo en el período 2010-2011 [Internet]. Edu.uy. Available from: http://www.scielo.edu.uy/pdf/rmu/v31n1/v31n1a05.pdf

Katzung, B.G. and Vanderah, T.W. Basic & amp. Clinical Pharmacology. 15th edn. New York, NY: McGraw-Hill; 2021.

Coupland C, Hill T, Morriss R, Moore M, Arthur A, Hippisley-Cox J. Antidepressant use and risk of adverse outcomes in people aged 20–64 years: cohort study using a primary care database. BMC Med. 2018;16(1).

Otero D, Petrovic M, Liao SL. Brugada phenocopy: A case of incessant ventricular tachycardia in a patient with tricyclic antidepressant overdose. Methodist Debakey Cardiovasc. J. 2020;16(3):245–248.

Ikejiri K, Akama Y, Ieki Y, Kawamoto E, Suzuki K, Yokoyama K, et al. Veno-arterial extracorporeal membrane oxygenation and targeted temperature management in tricyclic antidepressant-induced cardiac arrest: A case report and literature review: A case report and literature review. Medicine. 2021;100(9): e24980.

Nguyen H, Kidron A, Ghildyal C, Veluri S, Nguyen N, Nguyen Q, et al. Novel presentation of cardiotoxicity and other complications in tricyclic antidepressant poisoning. Cureus. 2021;13(8): e17181

Bai J, Zhu Y, Lo A, Gao M, Lu Y, Zhao J, et al. In silico assessment of class I antiarrhythmic drug effects on Pitx2-induced atrial fibrillation: Insights from populations of electrophysiological models of human atrial cells and tissues. Int. J. Mol. Sci. 2021;22(3):1265.

Scotton WJ, Hill LJ, Williams AC, Barnes NM. Serotonin syndrome: Pathophysiology, clinical features, management, and potential future directions. Int. J. Tryptophan Res. 2019;12: 1178646919873925.

Calvi A, Fischetti I, Verzicco I, Belvederi Murri M, Zanetidou S, Volpi R, et al. Antidepressant drugs effects on blood pressure. Front Cardiovasc. Med. 2021;8: 704281.

Francescangeli J, Karamchandani K, Powell M, Bonavia A. The serotonin syndrome: From molecular mechanisms to clinical practice. Int. J. Mol. Sci. 2019;20(9):2288.

Azofeifa MM, Chaves JCV, Jimenez SV, Diaz FA. Síndrome Serotoninérgico. Rev. Clin. Esc. Med. 2019;9(3):14–19.

Alborghetti M, Nicoletti F. Different generations of type-B monoamine oxidase inhibitors in Parkinson’s disease: From bench to bedside. Curr. Neuropharmacol. 2019;17(9):861–873.

Ostadkarampour M, Putnins EE. Monoamine oxidase inhibitors: A review of their anti-inflammatory therapeutic potential and mechanisms of action. Front Pharmacol. 2021;12: 676239.

Ogawa Y, Takeshima N, Hayasaka Y, Tajika A, Watanabe N, Streiner D, et al. Antidepressants plus benzodiazepines for adults with major depression. Cochrane Database Syst. Rev. 2019;6:CD001026.

Votaw VR, Geyer R, Rieselbach MM, McHugh RK. The epidemiology of benzodiazepine misuse: A systematic review. Drug Alcohol Depend. 2019;200: 95–114.

Casilla-Lennon MM, Meltzer-Brody S, Steiner AZ. The effect of antidepressants on fertility. Am. J. Obstet. Gynecol. 2016;215(3): 314.e1-5.

Uzunova V, Wrynn AS, Kinnunen A, Ceci M, Kohler C, Uzunov DP. Chronic antidepressants reverse cerebrocortical allopregnanolone decline in the olfactory-bulbectomized rat. Eur. J. Pharmacol. 2004;486(1):31–34.

Almeida FB, Pinna G, Barros HMT. The role of HPA axis and allopregnanolone on the neurobiology of major depressive disorders and PTSD. Int. J. Mol. Sci. 2021;22(11):5495.

Marzo VVN. Revista Digital de Medicina Psicosomática y Psicoterapia [Internet]. Psicociencias.org. 2023. Available from: https://www.psicociencias.org/pdf_noticias/Riesgo_suicidio_antidepresivos.pdf

Warden S, Spiwak R, Sareen J, Bolton JM. The SAD PERSONS scale for suicide risk assessment: a systematic review. Arch. Suicide. Res. 2014;18(4):313-326.

DOF - Diario Oficial de la Federación [Internet]. Gob.mx. 2023. Available from: https://www.dof.gob.mx/nota_detalle.php?codigo=5298031&fecha=06/05/2013

Lara-Aké NJ. Un panorama general de la atención farmacéutica en México. Rev. OFIL·ILAPHAR. 2020;30(4):334–336

Secretaría de Gobernacion. Ley General de Salud [Internet]. Diario Oficial de la Federacion. 2023. Disponible en: https://dof.gob.mx/nota_detalle.php?codigo=4652777&fecha=07/02/1984

La Asociación Mexicana de Escuelas y Facultades de Farmacia, A.C. (AMEFFAR) – Sitio web de AMEFFAR [Internet]. Org.mx. Available from: https://ameffar.org.mx/

Akande-Sholabi W, Ajamu AT, Adisa R. Prevalence, knowledge and perception of self-medication practice among undergraduate healthcare students. J. Pharm. Policy Pract. 2021;14(1):49.

Valdivia Pérez LG, Casique Casique L, Muñoz Torres T de J. Consumo de drogas psicotrópicas y capacidades de autocuidado en mujeres de Tepic, Nayarit. Enferm. Glob. 2015;14(1):65–75.

Rahimisadegh R, Sharifi N, Jahromi VK, Zahedi R, Rostayee Z, Asadi R. Self-medication practices and their characteristics among Iranian university students. BMC Pharmacol Toxicol. 2022;23(1):60.

Loni SB, Eid Alzahrani R, Alzahrani M, Khan MO, Khatoon R, Abdelrahman HH, et al. Prevalence of self-medication and associated factors among female students of health science colleges at Majmaah University: A cross-sectional study. Front Public Health. 2023;11: 1090021.

Vergès Y, Driot D, Deshayes C, Delahaye M, Oustric S, Dupouy J. Self-medication with psychotropic drugs and mental health during residency. A survey of 2314 resident physicians. La Presse Médicale Open. 2022;3(100017):100017.

Rentería M. Salud Mental en México [Internet]. 2018. Available from: https://www.foroconsultivo.org.mx/INCyTU/documentos/Completa/INCYTU_18-007.pdf

Maza JA, Aguilar LM, Mendoza JA. Farmacovigilancia: un paso importante en la seguridad del paciente. Rev. Sanid. Milit. 2018;72(1):47–53.

Published
2024-01-05
How to Cite
Mateos-Mauricio, F. A. (2024). Self-medication with anxiolytics and antidepressants: main risk factors and repercussions. Mexican Journal of Medical Research ICSA, 12(23), 6-13. https://doi.org/10.29057/mjmr.v12i23.11106